The short version
Just 2 companies supply this market — thin enough that a single exit would be felt immediately.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Mitoxantrone
Mitoxantrone · MITOXANTRONE HYDROCHLORIDE 2 mg/mL · Injection, Solution, Concentrate · Intravenous · Hospira, Inc.
NDC 61703-0343-18 · 1 VIAL, MULTI-DOSE in 1 CARTON / 10 mL in 1 VIAL, MULTI-DOSE · ANDA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Estimated fill cost
WAC per package, as filed
$172.56
Reported to Texas DSHS · 2026 annual filing · Pfizer Inc.
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Medicare Part B (ASP)
Payment limit per 5 MG
$29.702
HCPCS J9293 · Jul 1, 2026 quarter · typically ASP + 6%
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Where it's made
- analysis · label · manufacture · pack
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- ANDA076871
- TE code
- AP
- Approval date
- Apr 11, 2006
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
- Class I · TerminatedDec 3, 2014Hospira Inc. — Failed Stability Specifications: Product is subpotent and has out of specification known and unknown impurities.
Manufacturers of Mitoxantrone (Injection, Solution, Concentrate)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Meitheal Pharmaceuticals Inc. | MITOXANTRONE HYDROCHLORIDE 2 mg/mL | Jul 15, 2026 | Sep 3, 2026 |
| Hospira, Inc. | MITOXANTRONE HYDROCHLORIDE 2 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Mitoxantrone — NDC 61703-0343-18," retrieved September 3, 2026, https://drugdashboards.com/drug/61703034318.
Free to cite with attribution — see how the data is put together.